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Abstract
 Optimal histopathological analysis of biopsies from metastases of neuroendocrine tumor (NET) of the lung requires 
more than morphology only. Additional parameters such as Ki-67 labeling index are required for adequate diagnosis, 
but few studies have compared reproducibility of different counting protocols and modalities of reporting on biopsies of 
lung NET. We compared the results of four different manual counting techniques to establish Ki-67 LI. On 47 paired 
biopsies  and  surgical  specimens  from  22  typical  carcinoids  (TCs),  14  atypical  carcinoids  (ACs),  six  large  cell 
neuroendocrine carcinomas (LCNECs), and five small cell carcinomas (SCCs) immunohistochemical staining of Ki-67 
antigen was performed.We counted, in regions of highest nuclear s t a i n i n g (HSR), a f u l l °—40-high-power f i e ld 
(diameter = 0.55 mm), 500 or 2000 cells, or 2 mm2 surface area, including the HSR or the entire biopsy fragment(s). 
Mitoses and necrosis were evaluated in an area of 2 mm2 or the entire biopsy fragment(s). Between the four counting 
methods, no differences in Ki-67 LI were observed. However, a Ki-67 LI higher than 5% was found in only four cases 
when in an HSR, 500 cells were counted (18%), five (23%) when in an HSR 2000 cells were counted, four (18%) when 
2 mm2 were counted, and one (5%) TC case when the entire biopsy was counted. A 20% cutoff distinguished TC and 
AC from LCNEC and SCC with 100% specificity and sensitivity, while mitoses and necrosis failed to a large extent. 
Ki-67 LI in biopsy samples was concordant with that in resection specimens when 2000 cells, 2 mm2, or the entire 
biopsy fragment(s) were counted. Our results are important for clinical management of patients with metastases of a 
lung NET. 
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Introduction
Neuroendocrine  tumors  (NETs)  of  the  lung  are  a  heterogeneous  family  of  neoplasms  comprising  four  histologic 
variants: typical carcinoid (TC), atypical carcinoid (AC), largecell neuroendocrine carcinoma (LCNEC), and small-cell 
carcinoma (SCC) [1–6]. Classification criteria include cytological and histological features, the occurrence and extent of 
necrosis, the number of mitoses per 2 mm2, and the immunohistochemical (IHC) expression of pan-NE markers [1–3]. 
Although in comparison with previously proposed diagnostic schemes these criteria have been consolidated in the three
most  recent  WHO  classifications  [3,  7–12],  interindividual  diagnostic  reproducibility  for  these  tumors  remains 
disappointing,  likely  due  to  inconsistency  in  recognizing  necrosis,  mitoses,  and  cytological  details  [13–19]. 
Furthermore, diagnostic criteria have been established on surgical specimens but not validated on biopsies of lung NET, 
which therefore remain a diagnostic challenge with important clinical implications [1, 20–23]. Gastroenteropancreatic 
NE tumors (GEP-NETs) are graded on biopsies and resection specimens using both mitotic count and Ki-67 antigen 
labeling index (Ki-67 LI, the percentage of labeled nuclei after IHC staining), with clinical implications [24–27]. Ki-67 
is  a  generally  accepted  proliferation  marker  [28,  29],  and  the  Ki-67  LI  is  clinically  relevant  in  terms  of  guiding 
treatment decisions as supported by studies on a variety of tumors with confirming data [24–27]. The role of Ki-67 LI in 
lung NET has been the subject of several independent investigations, with potential diagnostic, prognostic, and grading 
implications (recently reviewed by Pelosi et al., 2014) [30]. Although differences in Ki-67 LI are reported between the 
four histological variants [3, 30], its significance as diagnostic criterion is contested [3] as there is overlap between the 
histological categories and Ki-67 LI are not perfectly congruent with other defining criteria [4–6, 30]. Currently, in lung 
NET, Ki-67 LI can only be used to distinguish between TC/AC from SCC on cytology and/or biopsy samples, notably 
when the volume of material is limited [3] and/or crush artifacts are present [31]. According to histology, TC, AC, and 
LCNEC/SCC indicate low-, intermediate-, and high-grade tumors, respectively [3]. However, the proportion of lung 
NET with similar histology that behave differently is not negligible,  which justifies further grading. As prognostic 
capability  has  been  attributed  to  Ki-67  LI  in  several  studies  [4–6,  19,  30],  it  can  be  used  for  grading  [32], 
complementary to conventional terminology [33]. At variance with the wide experience gained in performing Ki-67 LI 
in GEP-NET [24–27, 34], methodological studies on biopsy samples of lung NET are currently lacking, although they 
may be potentially helpful in planning treatment for metastatic tumors [22, 23]. On challenging material mitotic count 
and necrosis assessment tend not to be more informative, and NE marker IHC may provide disappointing results [21, 
31]. However, before authorizing diagnostic use of Ki-67 LI on biopsy samples, the accuracy and reproducibility of 
different counting methods are needed. In this study, we compared four techniques for manual counting of Ki-67 stained 
biopsy samples of lung NET and their corresponding surgical specimens.We found that identification of hot spot regions 
(HSR) and counting 2000 cells  or  a  2-mm2 surface area  including HSR or  the  entire  biopsy fragment(s),  reduces 
variability  in counting results.  Counting of  mitoses and estimation of  necrosis  did not  contribute to provide more 
reproducible results.
Materials and methods
Patients and tumors 
For this retrospective and observational investigation,  a series of 47 consecutive biopsies of lung NET and paired 
surgical specimens were identified in the archives of two participating Pathology Institutes (Milan and Turin), during 
the period from January 1983 to December 2014. This timeframe was due to the rarity of lung NET and our rather 
selective  inclusion  and  exclusion  criteria.  These  included  the  availability  of  corresponding  biopsy  and  resection 
specimens,  exclusion  of  unrepresentative  biopsies  (exclusive  fibrosis,  necrosis  or  inflammation  with  no  tumor 
components) or samples with fixation artifacts on which IHC turned out suboptimal, lack of a previous history of NET 
elsewhere in the body, and absence of chemotherapy before biopsy or surgery, to minimize changes in proliferation 
rates or amount of necrosis. The cohort comprised 45 lung and two thoracic lymph node biopsies (39 bronchoscopy
biopsies  and  eight  computed  tomography-guided  thoracic  biopsies),  with  corresponding  surgical  segmentectomy, 
lobectomy or  pneumonectomy specimens along with radical  mediastinal  lymph node dissection to ensure accurate 
staging. Biopsy and resection specimens had been fixed in 4% buffered formaldehyde solution for up to 24 h and 
embedded in paraffin according to standard laboratory methods. All original hematoxylin and eosin (H&E) and IHC-
stained sections were revised by two pairs of pathologists applying WHO classification-based criteria (for 27 Milan 
cases GP and MC; for 20 Turin cases LR and GG) without knowledge of patient identity or original tumor classification 
[35]. Assessment of interobserver variability was not a goal of the present study but significant differences were not 
observed between the two groups of pathologists in any assay. 
Immunohistochemistry 
Four micron sections were reacted for 30 min with antibodies to Ki-67 antigen, chromogranin A, and synaptophysin, 
and then incubated with a commercially available detection kit (DAKO EnVision Plus-HRP, Dako, Glostrup, Denmark) 
according to the manufacturer’s instructions and previously refined IHC methods [31, 36]. Technical details on IHC 
procedures are shown in Supplement a l  Mate r  i  a  l  A. Immunoreactivity was assessed semiquantitatively as the 
percentage of tumor cells showing nuclear (Ki-67) or cytoplasmic (chromogranin A and synaptophysin) decoration by 
visual scanning of the entire tumor area of stained sections for NE markers and discrete areas of highest nuclear labeling 
(hotspot  regions,  HSR) for  Ki-67 antigen [30].  A manual  cell  counter  was used to count  Ki-67 staining nuclei  to 
establish a LI,  the percentage of labeled tumor cells.  We used four counting approaches: the entire HSR at °—40 
magnification (field
diameter = 0.55mm; high-power field area = 0.237mm2), 500 or 2000 cells in the same HSR(s), and a 2-mm2 area 
including HSRs (on average 8.4) or the entire tumor fragment(s), when this was smaller. Mitoses were counted in a 2-
mm2 area  as  is  recommended in  current  diagnostic  guidelines  [3].  Necrosis  was  noted as  being absent  or  present 
regardless of extent. Statistical analysis Differences in the distribution of clinicopathological characteristics across the 
various histological tumor subtypes [3], and comparison between biopsies and surgical specimens or among different 
ways to count Ki-67 LI was assessed using the Fisher exact test for categorical variables (gender, site, pT, pN, stage), 
the non-parametric Kruskal-Wallis test for continuous variables (age), the non-parametric Wilcoxon signedrank test 
(biopsies vs. surgical specimens), and the repeated measures analysis (Ki-67 LI). Distribution of Ki67 LI for the various 
histological subtypes and according to the four counting techniques was also graphically represented using boxplots. 
Correlation and agreement between biopsies and surgical specimens for Ki-67 LI, mitotic count, and NE markers were 
also assessed using Deming regression, intraclass correlation coefficient (ICC), and Bland-Altman. graphical analysis 
[37].  Briefly,  interobserver  (within  material  type)  agreement  was  graphically  assessed  by  plotting  the  differences 
between the two measurements against the mean of the two values for each sample [37]. Limits of agreement, defined 
as twice the standard deviation of the differences between measures, were also calculated according to 95% confidence 
intervals. Differences between KI-67 LI in biopsies vs. surgical specimens were assessed using the Wilcoxon signed-
rank test, while differences between the four different manual counting techniques were assessed by repeated measure 
analysis, assuming unstructured covariance matrix based on a random effect model. Sensitivity and specificity of KI-67 
LI and chromogranin A to predict histological subtype was determined. Association of the presence of necrosis with 
histological and immunohistochemical variables was carried out using Fisher exact test for categorical variables and
McNemar’s test. All analyses were carried out using the SAS statistical software version 9.2 (SAS Institute, Inc., Cary, 
NC). All p values were two-sided and p values <0.05 were considered as significant.
Results
Our patient cohort consisted of 20 males (mean ± SD 58.5 ± 11.8; range 32–81 years) and 27 females (mean ± SD 51.7 
± 17.4; range 17–78 years). Of the tumors, 22 were stage IA, five stage IB, 10 stage IIA, four stage IIB, and six stage
IIIA [27]. Histological types are listed in Table 1, along with the type of material, presence, and quantity (as percentage) 
of necrosis; main histologic patterns (lobular, solid, or trabecular); and for biopsies, mean number and size of tissue
fragments. There were no differences between biopsy samples and surgical specimens in Ki-67 LI for lung NET as a 
whole or stratified by histology, except for the TC group when counting 500 tumor cells in an HSR (Table 2). No 
significant differences were observed either between biopsies and surgical specimens by counting 2000 cells and 2 mm2 
compared to 500 cells (Table 3). However, Ki-67 LI was higher than 5% in only four TC cases (18%) when 500 cells 
were counted in HSR, five (23%) when 2000 cells were counted in HSR, four (18%) when 2 mm2 were counted, and 
one (5%) when the entire tissue fragment was counted. Distribution of Ki-67 LI using 500 cell or
2 mm2 counting according to histological subtype in biopsies and surgical specimens is plotted in Fig. 1a, b and
Fig. 2a–h. We found for Ki-67 LI and neuroendocrine markers with all counting approaches an excellent correlation 
between biopsies and corresponding resection specimens by means of intraclass correlation coefficient analysis. For the 
NET subtypes, this correlation was weaker with a wider 95% confidence interval, likely due to the small 
number of tumors evaluated (Supplemental Material B). These findings were confirmed using Deming regression and 
Bland-Altman plot analysis, which show that differences between biopsy samples and surgical specimens
were consistent across the range of data (constant bias) (Supplemental Material C). On biopsy samples, a cutoff value 
for Ki-67 LI of 20% discriminated optimally between TC/AC and LCNEC/ SCC with 100% sensitivity and specificity, 
regardless of the used counting approach. For chromogranin A, this was less than perfect, with 82% sensitivity and 86% 
specificity (Table 4). Mitoses were recognizable in 38 out of 47 surgical specimens but in only 14 out of 45 biopsy 
samples (p = 0.000002) regardless of histological subtype, probably due to crush artifacts which prevented mitosis 
detection in  two biopsies.  For  mitotic  counts,  correlations  assessed with  intraclass  correlation coefficient,  Deming 
regression, and Bland-Altman plot analyses were low (Supplemental Material B and C). Necrosis was absent or present 
in both specimen types or only in surgical specimen or biopsies in 30, eight, nine, and no cases, respectively (p = 
0.00008, Fisher exact test; p = 0.002, McNemar’s test). Necrosis in biopsies predicted in 9 of 47 cases (47% sensitivity, 
100% specificity, 19% false negative results) its presence in resection specimens.
Discussion
In this paper, we describe methods to assess Ki-67 LI in biopsy specimens of lung NET and compare the results to those 
obtained on corresponding surgical specimens. We show that once HSRs have been identified, when counting
2000 cells,  2 mm2 including HSR(s) or  the entire biopsy,  fragment(s),  all  potential  discrepancies due to sampling, 
biopsy size, or intratumor heterogeneity of Ki-67 antigen distribution are eliminated, in all histological types. More 
specifically, Ki-67 LI provided the same level range in biopsy samples as in surgical specimens, thus allowing low- to 
intermediate-grade and high-grade tumors to be accurately separated when using a 20% cutoff threshold. Conversely, 
the presence of necrosis and mitotic activity failed to distinguish between low-, intermediate-, and
high-grade tumors. This methodological study paves the way to the use of Ki-67 LI in a daily diagnostic setting to 
characterize metastatic lung NET [21, 33, 38]. On surgical specimens of lung NET, some methodological studies on 
quantification of Ki-67 staining to generate a Ki-67 LI by manual or automated analysis systems have been performed 
[17, 19, 32, 39–41]. None, however, compared biopsies with corresponding surgical specimens, probably because in 
these tumors, the Ki-67 LI is not used for diagnosis or grading or as a prognostic factor [4, 6, 30], as morphology 
remains the favored approach [3]. However, when diagnosing lung NET, a distinction has to be made between low- to 
intermediate- and high-grade NET even when biopsies are small or crushed, to avoid errors in patient management and 
provide appropriate treatment adapted to the intrinsic aggressiveness of the disease which often cannot be done by 
morphology only [1, 20, 21, 31, 33, 38]. TC or AC is treated with somatostatin analogs, m-TOR pathway inhibitors, 
and/or peptide receptor radionuclide therapy (PRRT) [1, 4, 42–45], once imaging, symptoms, tumor burden, individual 
risks  of  evolving disease,  and actionable  targets  have been accounted for  [1,  21].  Once SCC has  been ruled out, 
metastatic  NETs  are  treated  with  PRRT or  alkylating-based  chemotherapy,  to  avoid  the  side  effects  of  platinum/
etoposide [42, 45]. Highly aggressive lung NETs, of which behavior and therapy would be similar to that of SCC, need 
to be distinguished from tumors with less predictable behavior based upon morphological characteristics, as they would 
merit biological treatment or nonplatinum-based chemotherapy [38, 42, 45]. In metastatic lung NET, the importance of 
the Ki-67 LI on biopsy samples is not so much the diagnosis as such (which paradoxically matters less once high-grade 
NET has been excluded) but rather to guide subsequent therapy choice [33]. This molecular, morphological, and clinical 
heterogeneity of lung NET [20, 39, 46–50] is similar to that of G3 GEP NET for which the Ki-67 LI is of equal 
diagnostic importance [26, 51–56]. Of note, LCNECs of the lung show a wide range of histological and molecular 
features, as some cases are morphologically close to SCCs [13, 14, 16, 47], while others are closer to conventional
non-small cell carcinoma [47, 57–59] and yet others to AC [3, 8, 47]. As a result, this is the tumor category with the 
lowest diagnostic reproducibility among lung NETs [18, 60, 61].We earlier reported values of Ki-67 LI in LCNECs 
ranging from 26 to 90% or higher [3, 30]. Along with the dilemmas in therapy choice, LCNECs are a waste-basket 
category with different genotypes and phenotypes (SCC-like LCNECs, NSCLC-like LCNECs, carcinoid-like LCNECs, 
as recently proposed) putatively reflecting plasticity of a cancer stem cell rather than a single entity with a characteristic 
profile  [47].We contend  that  integrated  classification  of  lung  NET,  merging  morphology  [62]  with  grading  which 
includes Ki-67 LI [32], might prove to be useful for clinical purposes [33]. In order to assess clinical usefulness, we 
assessed how on lung NET biopsies and corresponding resection specimens Ki-67 LI might be established and explored 
potential sources of variability. A Ki-67 LI can be established on small biopsy or cytology samples [31, 63–69], but 
studies comparing different counting methods are still lacking. We found that when on a biopsy 2000 cells, 2 mm2 , or 
the entire biopsy fragment(s) is counted, the result was the same as that on the surgical specimen, independent of tumor 
type, which implies that potential confounders such as biopsy size, tumor sampling, heterogeneity in distribution of 
Ki-67 staining, or subjective interpretation no longer interfere with the result. We only observed differences for TC, as 
Ki-67 LI exceeded 5% in only four (18%), five (23%), four (18%), and one (5%) TC case for counting in an HSR 500 
or 2000 cells or 2 mm2 /entire tissue fragment(s), but this is without consequences as all values remaining inside the 
category of well-differentiated lung NET [3]. Of note, we first proposed 2000 cells for pancreatic NET [28] and this is 
now the accepted standard in the ENETS grading system and WHO classification of neuroendocrine tumors [25–27]. 
The excellent correlation between Ki-67 LI on biopsies and surgical specimens was confirmed by intraclass correlation 
coefficient,  Deming regression and Bland-Altman plot  analyses,  in  spite  of  the large 95% confidence intervals  on 
subtypes, which is probably due to the small number of cases or lung NET with low proliferative activity [28, 29, 70] 
(Supplemental Material B). The basis for the establishment of a Ki-67 LI is the identification of HSR, which remains a 
matter of perception. We did not conduct an interobserver reproducibility study, but significant differences between two 
sets of 27 and 20 cases counted by two different pathologists in the two participating institutions were not found (data 
not shown). Counting 2000 cells (average 4.5 quantified fields) yielded the same result as counting 2 mm2 (average 8.4 
quantified  fields),  which  we  take  as  evidence  of  a  plateau  effect,  indicating  that  beyond  2000  cells,  no  further 
improvement can be obtained. Quantifying Ki-67 LI in HSR, as has become customary [19, 28, 30, 31, 40, 71–76], is 
methodologically sound and biologically relevant. Clinical relevance might be found in using Ki-67 LI on biopsies in a 
grading system of lung NET, as we recently proposed on surgical specimens by introducing the categories of Lu-NET 
G1, Lu-NET G2, and Lu-NET G3 [33]. We proposed a distinction between TC/AC and LCNEC/SCLC using a 20% 
cutoff value, which had 100% sensitivity and specificity in confirmation of our previous observations based on common 
sense [31]. Of note, this cutoff was very close to the 25% value, we recently proposed in a three-tier grading system of 
lung NET with the intention to highlight the intermediateprognosis G2 tumor category, which accommodated even 
some  LCNEC  [32].  Ki-67  LI  ranged  between  26  to  90%  in  LCNEC,  in  confirmation  of  its  inherent  biological 
heterogeneity. To distinguish between TC/AC and LCNEC/ SCLC, chromogranin A was less reliable as Ki-67 LI (Table 
4), which further credits Ki-67 LI as a valuable marker for lung NET with clinical implications. It is not surprising that 
necrosis and mitotic activity were unreliable criteria in biopsy samples, because these may be very focal or obscured by 
tissue artifacts due to sampling or processing, as reflected in significant differences in mitotic activity between biopsies 
and resection specimens (p = 0.000002) and 19% false-negative results on biopsies for necrosis when compared to the 
corresponding resection specimen. We contend that the lower diagnostic specificity of chromogranin A was more related 
to variable expression in morphologically similar high-grade NET [77] than to inadequate tumor sampling. A similar 
study has recently compared biopsy and surgical specimen results in GEP NET, based on virtual tissue microarray cores 
totaling a surface of 0.84 to 2.52 mm2 and whole tumor sections, with concordant results [78]. The authors used an 
image analysis system to generate a labeling index, while we chose visual counting using a manual counter to arrive at 
an approach applicable in daily practice where image analysis might not be available. Our procedure for counting tumor 
cells. on lung NET was not more time-consuming than were counting mitoses or apoptotic bodies or assessment of 
vascular invasion and avoided time-consuming setting up of image analysis [78, 79].
Conclusion
On biopsies of lung NET, a morphological diagnosis of carcinoid, SCLCs, and putatively LCNEC can be made [1, 3], 
when the Ki-67 LI is included as parameter but not necrosis, mitoses, or NE markers. This implies that Ki-67 LI can be 
used  reliably  on  biopsies  or  surgical  specimens  of  metastases,  for  comparison  with  the  primary  tumor,  either 
synchronous or metachronous. Manual counting in HSR of 2000 cells, 2mm2, or the entire tissue fragment(s) reduced 
biological and methodological intratumor heterogeneity due to sampling, tumor size, or subtype and provides a rationale 
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